Triple negative breast cancer (TNBC) accounts for 10-20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.12.010DOI Listing

Publication Analysis

Top Keywords

breast cancer
12
epidermal growth
8
growth factor
8
factor receptor
8
triple negative
8
negative breast
8
therapies tnbc
8
tnbc
5
targeting epidermal
4
receptor triple
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!